Measuring protein synthesis rates in lung cancer patients
Characterizing Tissue Protein Synthesis Rates of Non-small Cell Lung Carcinomas in Lung Cancer Patients
This study looks at how quickly proteins are made in lung cancer patients to see how cancerous lung tissue differs from healthy tissue and what factors might affect these rates.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 1 site (Heerlen, Limburg) |
| Trial ID | NCT05794529 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit lung cancer patients to measure and compare tissue protein synthesis rates between non-small cell lung carcinomas and healthy lung tissue. By analyzing these rates, the study seeks to establish the remodeling characteristics of cancerous versus healthy lung tissues. Additionally, it will explore associations between protein synthesis rates and various tumor and patient-derived parameters, such as tumor size, subclassification, inflammation, lung function, and smoking history.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who have been diagnosed with lung cancer and require surgical intervention.
Not a fit: Patients who have undergone neoadjuvant chemotherapy or radiotherapy in the past four weeks, or those with certain medical conditions such as insulin-dependent diabetes or pregnancy, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the biological differences between healthy and cancerous lung tissues, potentially leading to improved diagnostic and therapeutic strategies for lung cancer.
How similar studies have performed: While similar studies have explored protein synthesis in cancer, this specific approach focusing on lung cancer tissue comparison is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18-65 years 2. Compos mentis 3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy Exclusion Criteria: 1. Neoadjuvant chemo- or radiotherapy in the past four weeks 2. Use of systemic steroids in the past four week 3. Insulin-dependent diabetes mellitus 4. Pregnancy
Where this trial is running
Heerlen, Limburg
- Zuyderland Medical Center — Heerlen, Limburg, Netherlands (Recruiting)
Study contacts
- Study coordinator: Andrew Holwerda, PhD
- Email: andy.holwerda@maastrichtuniversity.nl
- Phone: +31433881381
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.